Latest On AC Immune SA (ACIU):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-28 16:17 EST | News | AC Immune GAAP EPS of -CHF0.21 | N/A |  |
| 2023-03-18 11:00 EST | News | AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures | N/A | |
| 2023-03-16 13:46 EST | News | AC Immune Non-GAAP EPS of -CHF 0.81, revenue of CHF 3.9M | N/A | |
| 2023-01-26 17:17 EST | News | AC Immune rises ~10% as Alzheimer’s vaccine shows promise in early-stage trial | N/A | |
| 2022-12-27 18:01 EST | News | Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket | N/A | |
About AC Immune SA (ACIU):
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phas read more...e Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
General
- Name AC Immune SA
- Symbol ACIU
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 115
- Fiscal Year EndDecember
- IPO Date2016-09-23
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.acimmune.com
Valuation
- Trailing PE 11.63
- Price/Sales (Trailing 12 Mt.) 33.12
- Price/Book (Most Recent Quarter) 2.25
- Enterprise Value Revenue 18.97
- Enterprise Value EBITDA 4.91
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.33
- Return on Assets -13%
- Return on Equity -24%
- Earnings Per Share -$0.55
- Revenue Per Share $0
- Gross Profit 60.59 million
- Quarterly Earnings Growth -96.6%
Highlights
- Market Capitalization 558.15 million
- Analyst Target Price $13.29
- Book Value Per Share $2.99
Share Statistics
- Shares Outstanding 71.74 million
- Shares Float 25.38 million
- % Held by Insiders 4699%
- % Held by Institutions 29.82%
- Shares Short 1.46 million
- Shares Short Prior Month 1.16 million
- Short Ratio 0.71
- Short % of Float 5%
- Short % of Shares Outstanding 2%
Technicals
- Beta 0.81
- 52 Week High $9.45
- 52 Week Low $4.42
- 50 Day Moving Average 7.55
- 200 Day Moving Average 6.17
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
AC Immune SA (ACIU) Dividend Calendar:
AC Immune SA (ACIU) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
AC Immune SA (ACIU) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
AC Immune SA (ACIU) Chart:
AC Immune SA (ACIU) News:
Below you will find a list of latest news for AC Immune SA (ACIU) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
AC Immune SA (ACIU) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ACIU Trades:
AC Immune SA (ACIU) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | EFFECT (Notice of Effectiveness) | |
| 2020-10-23 | F-3 (Registration statement by foreign private issuers) | |
| 2020-10-21 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-23 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-08 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-09-08 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-05 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-16 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-26 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-26 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-22 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-04 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-04-02 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-03-30 | 20-F (Annual and transition report of foreign private issuers [Sections 13 or 15(d)]) | |
| 2020-03-30 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-03-23 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-02-25 | UPLOAD (SEC-generated letter) | |
| 2020-02-14 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-02-07 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-02-06 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |